L-733,060

L-733,060
Clinical data
ATC code None
Identifiers
CAS Number 148700-85-0 YesY
PubChem (CID) 132846
ChemSpider 117244 N
ChEMBL CHEMBL27006 N
Chemical and physical data
Formula C20H19F6NO
Molar mass 403.361 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

L-733,060 is a drug developed by Merck which acts as an orally active, non-peptide, selective antagonist for the NK1 receptor, binding with a Ki of 0.08 nM.[1] Only one enantiomer is active which has made it the subject of several asymmetric synthesis efforts.[2][3][4]

L-733,060 has antidepressant[5][6] and anxiolytic effects in animal studies,[7] and reduces both the dopamine release and neurotoxicity produced by methamphetamine and cocaine.[8][9][10][11][12] It shows anti-inflammatory and anti-hepatotoxic effects in animals,[13][14] and counteracts the development of hyperalgesia following nerve injury.[15][16] It also has anticancer effects in a variety of in vitro models.[17][18][19]

See also

References

  1. ↑ Seabrook GR, Shepheard SL, Williamson DJ, Tyrer P, Rigby M, Cascieri MA, Harrison T, Hargreaves RJ, Hill RG (1996). "L-733,060, a novel tachykinin NK1 receptor antagonist; effects in Ca2+i mobilisation, cardiovascular and dural extravasation assays". European Journal of Pharmacology. 317 (1): 129–35. doi:10.1016/S0014-2999(96)00706-6. PMID 8982729.
  2. ↑ Liu LX, Ruan YP, Guo ZQ, Huang PQ (2004). "A general approach to (5S,6R)-6-alkyl-5-benzyloxy-2-piperidinones: application to the asymmetric syntheses of neurokinin substance P receptor antagonist (−)-L-733,061 and (−)-deoxocassine". The Journal of Organic Chemistry. 69 (18): 6001–9. doi:10.1021/jo049166z. PMID 15373484.
  3. ↑ Tsai MR, Chen BF, Cheng CC, Chang NC (2005). "A novel and highly regioselective approach to 5-methoxy-6-substituted-3-sulfonyl-delta-enlactams from 5-methoxy-3-sulfonyl glutarimide: synthesis of cis-2-substituted-3-piperidinols". The Journal of Organic Chemistry. 70 (5): 1780–5. doi:10.1021/jo048073e. PMID 15730301.
  4. ↑ Liu RH, Fang K, Wang B, Xu MH, Lin GQ (2008). "Concise asymmetric synthesis of (+)-CP-99,994 and (+)-L-733,060 via efficient construction of homochiral syn-1,2-diamines and syn-1,2-amino alcohols". The Journal of Organic Chemistry. 73 (8): 3307–10. doi:10.1021/jo8002979. PMID 18331063.
  5. ↑ Varty GB, Cohen-Williams ME, Hunter JC (2003). "The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test". Behavioural Pharmacology. 14 (1): 87–95. doi:10.1097/01.fbp.0000055962.09493.e9 (inactive 2015-01-14). PMID 12576885.
  6. ↑ Wallace-Boone TL, Newton AE, Wright RN, Lodge NJ, McElroy JF (2008). "Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists". Neuropsychopharmacology. 33 (8): 1919–28. doi:10.1038/sj.npp.1301586. PMID 17912250.
  7. ↑ Varty GB, Cohen-Williams ME, Morgan CA, Pylak U, Duffy RA, Lachowicz JE, Carey GJ, Coffin VL (2002). "The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists". Neuropsychopharmacology. 27 (3): 371–9. doi:10.1016/S0893-133X(02)00313-5. PMID 12225694.
  8. ↑ Kraft M, Noailles P, Angulo JA (2001). "Substance P modulates cocaine-evoked dopamine overflow in the striatum of the rat brain". Annals of the New York Academy of Sciences. 937: 121–31. Bibcode:2001NYASA.937..121K. doi:10.1111/j.1749-6632.2001.tb03561.x. PMID 11458533.
  9. ↑ Yu J, Allison S, Ibrahim D, Cadet JL, Angulo JA (2002). "Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain". Annals of the New York Academy of Sciences. 965: 247–53. Bibcode:2002NYASA.965..247Y. doi:10.1111/j.1749-6632.2002.tb04166.x. PMID 12105100.
  10. ↑ Noailles PA, Angulo JA (2002). "Neurokinin receptors modulate the neurochemical actions of cocaine". Annals of the New York Academy of Sciences. 965: 267–73. Bibcode:2002NYASA.965..267N. doi:10.1111/j.1749-6632.2002.tb04168.x. PMID 12105102.
  11. ↑ Yu J, Cadet JL, Angulo JA (2002). "Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain". Journal of Neurochemistry. 83 (3): 613–22. doi:10.1046/j.1471-4159.2002.01155.x. PMID 12390523.
  12. ↑ Loonam TM, Noailles PA, Yu J, Zhu JP, Angulo JA (2003). "Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum". Life Sciences. 73 (6): 727–39. doi:10.1016/S0024-3205(03)00393-X. PMID 12801594.
  13. ↑ Bang R, Sass G, Kiemer AK, Vollmar AM, Neuhuber WL, Tiegs G (2003). "Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury". The Journal of Pharmacology and Experimental Therapeutics. 305 (1): 31–9. doi:10.1124/jpet.102.043539. PMID 12649350.
  14. ↑ Bang R, Biburger M, Neuhuber WL, Tiegs G (2004). "Neurokinin-1 receptor antagonists protect mice from CD95- and tumor necrosis factor-alpha-mediated apoptotic liver damage". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 1174–80. doi:10.1124/jpet.103.059329. PMID 14617692.
  15. ↑ Jang JH, Nam TS, Paik KS, Leem JW (2004). "Involvement of peripherally released substance P and calcitonin gene-related peptide in mediating mechanical hyperalgesia in a traumatic neuropathy model of the rat". Neuroscience Letters. 360 (3): 129–32. doi:10.1016/j.neulet.2004.02.043. PMID 15082150.
  16. ↑ Rittner HL, Lux C, Labuz D, Mousa SA, Schäfer M, Stein C, Brack A (2007). "Neurokinin-1 receptor antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral antinociception". Anesthesiology. 107 (6): 1009–17. doi:10.1097/01.anes.0000291454.90754.de. PMID 18043070.
  17. ↑ Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (2007). "Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138". Investigative Ophthalmology & Visual Science. 48 (6): 2775–81. doi:10.1167/iovs.05-1591. PMID 17525212.
  18. ↑ Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F (2008). "NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2". Investigational new drugs. 26 (2): 111–8. doi:10.1007/s10637-007-9087-y. PMID 17906845.
  19. ↑ Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M (2008). "The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines". Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 29 (4): 245–54. doi:10.1159/000152942. PMID 18781096.
This article is issued from Wikipedia - version of the 11/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.